Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation

World Journal of Hepatology

Volumn 7, Issue 11, 2015, Pages 1494-1508

  Kornberg, Arno ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Hyperimmunoglobulin; Immune modulation; Intravenous immunoglobulins; Liver transplantation; Model of end stage liver disease

Indexed keywords

EID: 84930853859     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i11.1494     Document Type: Review

References (177)

1. Bhamidimarri KR, Martin P. Liver transplantation: update of concepts and practice. Clin Liver Dis 2014; 18: xiii-xxiv [PMID:25017087]
2. Yang LS, Shan LL, Saxena A, Morris DL. Liver transplantation: a systematic review of long-term quality of life. Liver Int 2014; 34:1298-1313 [PMID: 24703371 DOI: 10.1111/liv.12553]
3. Saidi RF, Hejazii Kenari SK. Clinical transplantation and tolerance:are we there yet? Int J Organ Transplant Med 2014; 5: 137-145 [PMID: 25426282]
4. Alqahtani SA. Update in liver transplantation. Curr Opin Gastroenterol 2012; 28: 230-238 [PMID: 22450898 DOI: 10.1097/ MOG.0b013e3283527f16]
5. Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Excess mortality on the liver transplant waiting list:unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. Hepatology 2015; 61: 285-291 [PMID:24995689 DOI: 10.1002/hep.27283]
6. Cholongitas E, Burroughs AK. The evolution in the prioritization for liver transplantation. Ann Gastroenterol 2012; 25: 6-13 [PMID:24713804]
7. Hong G, Lee KW, Suh S, Yoo T, Kim H, Park MS, Choi Y, Yi NJ, Suh KS. The model for end-stage liver disease score-based system predicts short term mortality better than the current Child-Turcotte-Pugh score-based allocation system during waiting for deceased liver transplantation. J Korean Med Sci 2013; 28: 1207-1212 [PMID: 23960449 DOI: 10.3346/jkms.2013.28.8.1207]
8. Lau T, Ahmad J. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med 2013; 5:1-10 [PMID: 24696621 DOI: 10.2147/HMER.S9049]
9. Dutkowski P, Oberkofler CE, Béchir M, Müllhaupt B, Geier A, Raptis DA, Clavien PA. The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis. Liver Transpl 2011; 17: 674-684 [PMID: 21618688 DOI: 10.1002/lt.22228]
10. Quante M, Benckert C, Thelen A, Jonas S. Experience Since MELD Implementation: How Does the New System Deliver? Int J Hepatol 2012; 2012: 264015 [PMID: 23091734 DOI:10.1155/2012/264015]
11. Weismüller TJ, Negm A, Becker T, Barg-Hock H, Klempnauer J, Manns MP, Strassburg CP. The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transpl Int 2009; 22: 970-978 [PMID: 19619170 DOI: 10.1111/j.1432-2277.2009]
12. Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, Paul A, Scherer MN, Schmidt HH, Schlitt HJ, Neuhaus P, Klempnauer J, Pratschke J, Manns MP, Strassburg CP. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int 2011; 24:91-99 [PMID: 20819196 DOI: 10.1111/j.1432-2277.2010.01161.x]
13. Schlitt HJ, Loss M, Scherer MN, Becker T, Jauch KW, Nashan B, Schmidt H, Settmacher U, Rogiers X, Neuhaus P, Strassburg C. [Current developments in liver transplantation in Germany:MELD-based organ allocation and incentives for transplant centres]. Z Gastroenterol 2011; 49: 30-38 [PMID: 21225535 DOI:10.1055/s-0029-1245946]
14. Otto G. Liver transplantation: an appraisal of the present situation. Dig Dis 2013; 31: 164-169 [PMID: 23797139 DOI:10.1159/000347213]
15. Harring TR, O'Mahony CA, Goss JA. Extended donors in liver transplantation. Clin Liver Dis 2011; 15: 879-900 [PMID:22032534 DOI: 10.1016/j.cld.2011.08.006]
16. Chung HY, Chan SC, Lo CM, Fan ST. Strategies for widening liver donor pool. Asian J Surg 2010; 33: 63-69 [PMID: 21029941 DOI: 10.1016/S1015-9584(10)60011-5]
17. Zarrinpar A, Busuttil RW. Immunomodulating options for liver transplant patients. Expert Rev Clin Immunol 2012; 8: 565-578; quiz 578 [PMID: 22992151]
18. Cravedi P, Heeger PS. Immunologic monitoring in transplantation revisited. Curr Opin Organ Transplant 2012; 17: 26-32 [PMID:22186089 DOI: 10.1097/MOT.0b013e32834ee402]
19. Fernández-Ruiz M, Kumar D, Humar A. Clinical immunemonitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunology 2014; 3: e12 [PMID:25505960 DOI: 10.1038/cti.2014.3]
20. Sewell WA, Kerr J, Behr-Gross ME, Peter HH. European consensus proposal for immunoglobulin therapies. Eur J Immunol 2014; 44:2207-2214 [PMID: 24975475 DOI: 10.1002/eji.201444700]
21. Boros P, Gondolesi G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl 2005; 11: 1469-1480 [PMID: 16315304]
22. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29: 608-615 [PMID:18926775 DOI: 10.1016/j.it.2008.08.004]
23. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-1231 [PMID:6112565]
24. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755 [PMID: 11547745]
25. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin:appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 117-130 [PMID: 11939601]
26. Jordan SC, Peng A, Vo AA. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. Contrib Nephrol 2009; 162: 13-26 [PMID: 19001810 DOI: 10.1159/000170864]
27. John R, Lietz K, Burke E, Schuster M, Yen E, Naka Y, Mancini D, Edwards N, Oz M, Itescu S. Intravenous immunoglobulin therapy in highly sensitized cardiac allograft recipients facilitates transplantation across donor specific IGG positive cross matches. J Heart Lung Transplant 2001; 20: 213 [PMID: 11250390]
28. Sarmiento E, Fernàndez-Yáñez J, Muñoz P, Palomo J, Rodríguez-Molina JJ, Bermejo J, Catalan P, Bouza E, Fernández-Cruz E, Carbone J. Hypogammaglobulinemia after heart transplantation:use of intravenous immunoglobulin replacement therapy in relapsing CMV disease. Int Immunopharmacol 2005; 5: 97-101 [PMID: 15589466]
29. Manne V, Allen RM, Saab S. Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation. Gastroenterol Hepatol (NY) 2014; 10: 175-179 [PMID: 24829544]
30. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy:how does IgG modulate the immune system? Nat Rev Immunol 2013; 13: 176-189 [PMID: 23411799 DOI: 10.1038/nri3401]
31. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367: 2015-2025 [PMID: 23171098 DOI: 10.1056/NEJMra1009433]
32. Ferrara G, Zumla A, Maeurer M. Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections. Am J Med 2012; 125: 1036.e1-1036.e8 [PMID: 22608788 DOI: 10.1016/ j.amjmed.2012.01.023]
33. Sultan Y, Kazatchkine MD, Nydegger U, Rossi F, Dietrich G, Algiman M. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII: C inhibitors. Am J Med 1991; 91: 35S-39S [PMID: 1746595]
34. Mitrevski M, Marrapodi R, Camponeschi A, Cavaliere FM, Lazzeri C, Todi L, Visentini M. Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects. Front Immunol 2015; 6: 4 [PMID: 25657650 DOI: 10.3389/ fimmu.2015.00004]
35. van Mirre E, Teeling JL, van der Meer JW, Bleeker WK, Hack CE. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIb. J Immunol 2004; 173: 332-339 [PMID: 15210791]
36. Galeotti C, Kaveri SV, Bayry J. Molecular and immunological biomarkers to predict IVIg response. Trends Mol Med 2015; 21:145-147 [PMID: 25680699 DOI: 10.1016/j.molmed.2015.01.005]
37. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725 [PMID: 17703228]
38. Machimoto T, Guerra G, Burke G, Fricker FJ, Colona J, Ruiz P, Meier-Kriesche HU, Scornik J. Effect of IVIG administration on complement activation and HLA antibody levels. Transpl Int 2010; 23: 1015-1022 [PMID: 20412537 DOI: 10.1111/j.14322277.2010]
39. Andersson UG, Björk L, Skansén-Saphir U, Andersson JP. Downregulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211-216 [PMID: 8344700]
40. Figueiredo CA, Drohomyrecky PC, McCarthy SD, Leontyev D, Ma XZ, Branch DR, Dunn SE. Optimal attenuation of experimental autoimmune encephalomyelitis by intravenous immunoglobulin requires an intact interleukin-11 receptor. PLoS One 2014; 9:e101947 [PMID: 25078447 DOI: 10.1371/journal.pone.0101947]
41. Pigard N, Elovaara I, Kuusisto H, Paalavuo R, Dastidar P, Zimmermann K, Schwarz HP, Reipert B. Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression. J Neuroimmunol 2009; 209:114-120 [PMID: 19217671]
42. Tjon AS, van Gent R, Jaadar H, Martin van Hagen P, Mancham S, van der Laan LJ, te Boekhorst PA, Metselaar HJ, Kwekkeboom J. Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production. J Immunol 2014; 192: 5625-5634 [PMID: 24808368 DOI: 10.4049/jimmunol.1301260]
43. Kwekkeboom J. Modulation of dendritic cells and regulatory T cells by naturally occurring antibodies. Adv Exp Med Biol 2012; 750: 133-144 [PMID: 22903671 DOI: 10.1007/978-1-4614-3461-0_10]
44. Crow AR, Brinc D, Lazarus AH. New insight into the mechanism of action of IVIg: the role of dendritic cells. J Thromb Haemost 2009; 7 Suppl 1: 245-248 [PMID: 19630809 DOI: 10.1111/ j.1538-7836.2009.03420.x]
45. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758-765 [PMID: 12393386]
46. Tha-In T, Metselaar HJ, Tilanus HW, Boor PP, Mancham S, Kuipers EJ, de Man RA, Kwekkeboom J. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation 2006; 81:1725-1734 [PMID: 16794540]
47. Ziętara N, Łyszkiewicz M, Krueger A, Weiss S. B-cell modulation of dendritic-cell function: signals from the far side. Eur J Immunol 2014; 44: 23-32 [PMID: 24307285]
48. Koski CL, Patterson JV. Intravenous immunoglobulin use for neurologic diseases. J Infus Nurs 2006; 29: S21-S28 [PMID:16878852]
49. Modiano JF, Amran D, Lack G, Bradley K, Ball C, Domenico J, Gelfand EW. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin. Clin Immunol Immunopathol 1997; 83: 77-85 [PMID: 9073539]
50. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73: 180-186 [PMID: 7523013]
51. Grosse-Wilde H, Blasczyk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 1992; 39: 74-77 [PMID: 1574801]
52. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, Kazatchkine MD. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1994; 1: 269-277 [PMID:7584501]
53. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992; 89: 3325-3329 [PMID: 1565623]
54. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182:18-32 [PMID: 11722621]
55. Tjon AS, Tha-In T, Metselaar HJ, van Gent R, van der Laan LJ, Groothuismink ZM, te Boekhorst PA, van Hagen PM, Kwekkeboom J. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol 2013; 173: 259-267 [PMID: 23607448]
56. Cousens L, Najafian N, Martin WD, De Groot AS. Tregitope:Immunomodulation powerhouse. Hum Immunol 2014; 75: 1139-1146 [PMID: 25454619 DOI: 10.1016/j. humimm.2014.10.012]
57. Pipili C, Cholongitas E. Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol 2014; 6: 315-325 [PMID: 24868325 DOI: 10.4254/wjh. v6.i5.315]
58. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-S85 [PMID: 15382222]
59. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, Brechot C, Bismuth H. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813-815 [PMID: 1672913]
60. Wong TC, Fung JY, Lo CM. Prevention of recurrent hepatitis B infection after liver transplantation. Hepatobiliary Pancreat Dis Int 2013; 12: 465-472 [PMID: 24103275]
61. Congly SE, Burak KW, Coffin CS. Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation. Expert Rev Clin Immunol 2011; 7: 429-436 [PMID: 21790285 DOI: 10.1586/eci.11.30]
62. Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, Samuel D. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl 2010; 16: 885-894 [PMID: 20583085 DOI: 10.1002/lt.22084]
63. Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19: 9189-9197 [PMID: 24409047 DOI: 10.3748/wjg.v19.i48.9189]
64. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: metaanalysis. Clin Gastroenterol Hepatol 2008; 6: 696-700 [PMID:18456569 DOI: 10.1016/j.cgh.2008.02.055]
65. Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12: 292-308 [PMID:20002355 DOI: 10.1111/j.1399-3062.2009.00470.x]
66. Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009; 22: 387-394 [PMID: 19017304 DOI: 10.1111/j.1432-2277.2008.00784.x]
67. Chen J, Yi L, Jia JD, Ma H, You H. Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review. J Gastroenterol Hepatol 2010; 25: 872-879 [PMID: 20546440 DOI: 10.1111/.1440-1746.2009.06151.x]
68. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013; 13: 353-362 [PMID: 23137006 DOI: 10.1111/ j.1600-6143.2012.04315.x]
69. Dindoost P, Jazayeri SM, Alavian SM. Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Mon 2012; 12: 168-176 [PMID: 22550524 DOI: 10.5812/hepatmon.832]
70. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardí R, Cruz de Castro E, García-Rey C. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with longterm lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-817 [PMID: 12763375]
71. Xi ZF, Xia Q. Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015; 21: 829-835 [PMID: 25624716 DOI: 10.3748/wjg.v21.i3.829]
72. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219 [PMID: 21762659 DOI: 10.1053/j.gastro.2011.06.083]
73. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14:479-487 [PMID: 22624695 DOI: 10.1111/j.1399-3062.2012.00741. x]
74. Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V, Akriviadis E. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int 2014; 27:1022-1028 [PMID: 24909714 DOI: 10.1111/tri.12370]
75. Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012; 56: 1189-1197 [PMID:22274310 DOI: 10.1016/j.jhep.2011.08.026]
76. Hu TH, Chen CL, Lin CC, Wang CC, Chiu KW, Yong CC, Liu YW, Eng HL. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Transplantation 2014; 97 Suppl 8: S53-S59 [PMID: 24849836 DOI: 10.1097/01. tp.0000446278.43804.f9]
77. Tanaka T, Renner EL, Selzner N, Therapondos G, Lilly LB. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. Can J Gastroenterol Hepatol 2014; 28: 41-44 [PMID: 24212911]
78. Wadhawan M, Gupta S, Goyal N, Taneja S, Kumar A. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. Liver Transpl 2013; 19: 1030-1035 [PMID: 23788470 DOI: 10.1002/lt.23692]
79. Gao YJ, Zhang M, Jin B, Meng FP, Ma XM, Liu ZW, Su HB, Zhao JM, Li HW. Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. J Gastroenterol Hepatol 2014; 29: 554-560 [PMID: 24117714 DOI:10.1111/jgh.12404]
80. Farges O, Saliba F, Farhamant H, Samuel D, Bismuth A, Reynes M, Bismuth H. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology 1996; 23: 240-248 [PMID: 8591847]
81. Couto CA, Bittencourt PL, Farias AQ, Lallee MP, Cançado EL, Massarollo PC, Mies S. Human polyclonal anti-hepatitis B surface antigen immunoglobulin reduces the frequency of acute rejection after liver transplantation for chronic hepatitis B. Rev Inst Med Trop Sao Paulo 2001; 43: 335-337 [PMID: 11781604]
82. Kwekkeboom J, Tha-In T, Tra WM, Hop W, Boor PP, Mancham S, Zondervan PE, Vossen AC, Kusters JG, de Man RA, Metselaar HJ. Hepatitis B immunoglobulins inhibit dendritic cells and T cells and protect against acute rejection after liver transplantation. Am J Transplant 2005; 5: 2393-2402 [PMID: 16162187]
83. Wang P, Tam N, Wang H, Zheng H, Chen P, Wu L, He X. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One 2014; 9: e104480 [PMID: 25102072 DOI: 10.1371/journal. pone.0104480]
84. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, Zetterman RK, Pruett TL, Ishitani MB, Hoofnagle JH. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113:1668-1674 [PMID: 9352871]
85. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, Iwatsuki S, Montalvo E, Rakela J, Fung JJ. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64: 1582-1584 [PMID: 9415560]
86. Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7: 51-58 [PMID: 11150423]
87. Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002; 8: 556-561 [PMID: 12037788]
88. Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 2006; 20: 369-373 [PMID: 16824156]
89. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3: 105-111 [PMID: 9346723]
90. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 1058-1061 [PMID: 10532552]
91. Lei J, Yan L, Wang W. A comprehensive study of the safety of using anti-hepatitis B core (Hbc) positive subjects in living donor liver transplants. Hepatogastroenterology 2013; 60: 1426-1432 [PMID: 23933935]
92. Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, Jawan B, Chiu KW, Chen CL. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16: 405-409 [PMID: 12437618]
93. de Villa VH, Chen YS, Chen CL. Hepatitis B core antibodypositive grafts: recipient's risk. Transplantation 2003; 75: S49-S53 [PMID: 12589141]
94. Brock GN, Mostajabi F, Ferguson N, Carrubba CJ, Eng M, Buell JF, Marvin MR. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl Int 2011; 24: 570-581 [PMID: 21401727 DOI: 10.1111/j.1432-2277.2011.01236.x]
95. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52: 272-279 [PMID: 20034693 DOI: 10.1016/ j.jhep.2009.11.009]
96. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, Kiuchi T, Miyake Y, Tanaka K, Chiba T. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494-499 [PMID: 9500622]
97. Loss GE, Mason AL, Blazek J, Dick D, Lipscomb J, Guo L, Perrillo RP, Eason JD. Transplantation of livers from hbc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clin Transplant 2001; 15 Suppl 6: 55-58 [PMID: 11903388]
98. Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137: 572-575; discussion 575-576 [PMID: 11982471]
99. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7: 513-517 [PMID: 11443579]
100. De Vera ME, Eghtesad D, Tom K. Liver transplantations of HBcAb and HCV allografts. ATC 2005: 6th Annual Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. 2005: Abstract 1138
101. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50: 95-99 [PMID:11772974]
102. Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI, Ghobrial RM, Busuttil RW. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003; 9: 1053-1061 [PMID: 14526400]
103. Bortoluzzi I, Gambato M, Albertoni L, Mescoli C, Pacenti M, Cusinato R, Germani G, Senzolo M, Rugge M, Boccagni P, Zanus G, Cillo U, Burra P, Russo FP. Use of grafts from anti-HBc-positive donors in liver transplantation: a 5-year, single-center experience. Transplant Proc 2013; 45: 2707-2710 [PMID: 24034028 DOI:10.1016/j.transpproceed.2013.07.049]
104. Choi Y, Choi JY, Yi NJ, Lee K, Mori S, Hong G, Kim H, Park MS, Yoo T, Suh SW, Lee HW, Lee KW, Suh KS. Liver transplantation for HBsAg-positive recipients using grafts from HBsAg-positive deceased donors. Transpl Int 2013; 26: 1173-1183 [PMID: 24131436 DOI: 10.1111/tri.12177]
105. González-Peralta RP, Andres JM, Tung FY, Fang JW, Brunson ME, Davis GL, Lau JY. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. Transplantation 1994; 58: 114-116 [PMID: 8036699]
106. Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922-928 [PMID: 16035057]
107. Ho JK, Harrigan PR, Sherlock CH, Steinbrecher UP, Erb SR, Mo T, Chung SW, Buczkowski AK, Intaraprasong P, Scudamore CH, Yoshida EM. Utilization of a liver allograft from a hepatitis B surface antigen positive donor. Transplantation 2006; 81: 129-131 [PMID: 16421489]
108. Hwang S, Lee SG, Park KM, Kim KH, Ahn CS, Oh HB, Moon DB, Ha TY, Lim YS, Jung DH. Five-year follow-up of a hepatitis B virus-positive recipient of hepatitis B surface antigen-positive living donor liver graft. Liver Transpl 2006; 12: 993-997 [PMID:16721765]
109. Jiang L, Yan L, Li B, Wen T, Zhao J, Jiang L, Yang J, Xu M, Wang W. Successful use of hepatitis B surface antigen-positive liver grafts in recipients with hepatitis B virus-related liver diseases. Liver Transpl 2011; 17: 1236-1238 [PMID: 21748846 DOI:10.1002/lt.22379]
110. Loggi E, Micco L, Ercolani G, Cucchetti A, Bihl FK, Grazi GL, Gitto S, Bontadini A, Bernardi M, Grossi P, Costa AN, Pinna AD, Brander C, Andreone P. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol 2012; 56: 579-585 [PMID: 22027583 DOI:10.1016/j.jhep.2011.09.016]
111. Saidi RF, Hejazi Kenari SK. Liver transplantation for hepatocellular carcinoma: past, present and future. Middle East J Dig Dis 2013; 5: 181-192 [PMID: 24829690]
112. Li Z, Hu Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Use of hepatitis B surface antigen-positive grafts in liver transplantation: a matched analysis of the US National database. Liver Transpl 2014; 20: 35-45 [PMID: 24142889 DOI: 10.1002/lt.23774]
113. Ju W, Chen M, Guo Z, Wang D, Zhu X, Huang J, He X. Allografts positive for hepatitis B surface antigen in liver transplant for disease related to hepatitis B virus. Exp Clin Transplant 2013; 11:245-249 [PMID: 23176583 DOI: 10.6002/ect.2012.0095]
114. Saliba F, Arulnaden JL, Gugenheim J, Serves C, Samuel D, Bismuth A, Mathieu D, Bismuth H. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc 1989; 21: 2260-2262 [PMID:2540564]
115. Bruminhent J, Razonable RR. Management of cytomegalovirus infection and disease in liver transplant recipients. World J Hepatol 2014; 6: 370-383 [PMID: 25018848]
116. Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother 2013; 45:260-271 [PMID: 24396627 DOI: 10.3947/ic.2013.45.3.260]
117. O'Grady JG, Alexander GJ, Sutherland S, Donaldson PT, Harvey F, Portmann B, Calne RY, Williams R. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent cofactors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988; 2: 302-305 [PMID: 2899720]
118. Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RA. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476-483 [PMID: 3552923]
119. Madalosso C, de Souza NF, Ilstrup DM, Wiesner RH, Krom RA. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998; 66: 294-297 [PMID: 9721795]
120. Eid AJ. Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities. Curr Opin Organ Transplant 2007; 12: 610-617 [DOI: 10.1097/ MOT.0b013e3282f0d386]
121. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 1997; 11:432-437 [PMID: 9361936]
122. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMVhyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008; 22: 89-97 [PMID: 18217909 DOI: 10.1111/ j.1399-0012.2007.00750.x]
123. van Gent R, Jaadar H, Tjon AS, Mancham S, Kwekkeboom J. T-cell inhibitory capacity of hyperimmunoglobulins is influenced by the production process. Int Immunopharmacol 2014; 19:142-144 [PMID: 24462495 DOI: 10.1016/j.intimp.2014.01.007]
124. Bucuvalas JC, Anand R. Treatment with immunoglobulin improves outcome for pediatric liver transplant recipients. Liver Transpl 2009; 15: 1564-1569 [PMID: 19877216 DOI: 10.1002/ lt.21843]
125. Fisher RA, Kistler KD, Ulsh P, Bergman GE, Morris J. The association between cytomegalovirus immune globulin and longterm recipient and graft survival following liver transplantation. Transpl Infect Dis 2012; 14: 121-131 [PMID: 21883757 DOI:10.1111/j.1399-3062.2011.00664.x]
126. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients:an evidence-based reassessment of safety and efficacy. PLoS One 2009; 4: e5512 [PMID: 19436751 DOI: 10.1371/journal. pone.0005512]
127. Magee CC. Transplantation across previously incompatible immunological barriers. Transpl Int 2006; 19: 87-97 [PMID:16441356]
128. Iyer HS, Jackson AM, Zachary AA, Montgomery RA. Transplanting the highly sensitized patient: trials and tribulations. Curr Opin Nephrol Hypertens 2013; 22: 681-688 [PMID:24076558 DOI: 10.1097/MNH.0b013e328365b3b9]
129. Morath C, Schmidt J, Opelz G, Zeier M, Süsal C. Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch? Langenbecks Arch Surg 2011; 396: 467-474 [PMID: 21416127 DOI: 10.1007/s00423-011-0759-x]
130. Sharif A, Alachkar N, Kraus E. Incompatible kidney transplantation:a brief overview of the past, present and future. QJM 2012; 105:1141-1150 [PMID: 22908321 DOI: 10.1093/qjmed/ hcs154]
131. Bucin D, Johansson S, Malm T, Jögi P, Johansson J, Westrin P, Lindberg LO, Olsson AK, Gelberg J, Peres V, Harling S, Bennhagen R, Kornhall B, Ekmehag B, Kurkus J, Otto G. Heart transplantation across the antibodies against HLA and ABO. Transpl Int 2006; 19: 239-244 [PMID: 16441774]
132. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326 [PMID: 21793744 DOI: 10.1056/NEJMoa1012376]
133. Al-Mohaissen MA, Virani SA. Allosensitization in heart transplantation:an overview. Can J Cardiol 2014; 30: 161-172 [PMID:24373761 DOI: 10.1016/j.cjca.2013.10.017]
134. Campbell P. Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation. Curr Opin Organ Transplant 2013; 18: 463-469 [PMID: 23838652 DOI:10.1097/MOT.0b013e3283636c71]
135. O'Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, Knechtle SJ, McDiarmid SV, Shaked A, Terasaki PI, Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle ES, Zachary AA, Klintmalm GB. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014; 14: 779-787 [PMID:24580828 DOI: 10.1111/ajt.12667]
136. Ruiz R, Tomiyama K, Campsen J, Goldstein RM, Levy MF, McKenna GJ, Onaca N, Susskind B, Tillery GW, Klintmalm GB. Implications of a positive crossmatch in liver transplantation: a 20-year review. Liver Transpl 2012; 18: 455-460 [PMID: 22139972 DOI: 10.1002/lt.22474]
137. Leonard GR, Shike H, Uemura T, Gaspari JL, Ruggiero FM, Shah RA, Riley TR, Kadry Z. Liver transplantation with a strongly positive crossmatch: case study and literature review. Liver Transpl 2013; 19: 1001-1010 [PMID: 23798324 DOI: 10.1002/lt.23694]
138. Iwatsuki S, Rabin BS, Shaw BW, Starzl TE. Liver transplantation against T cell-positive warm crossmatches. Transplant Proc 1984; 16: 1427-1429 [PMID: 6390842]
139. Gordon RD, Fung JJ, Markus B, Fox I, Iwatsuki S, Esquivel CO, Tzakis A, Todo S, Starzl TE. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705-715 [PMID: 3532391]
140. Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, Terasaki PI. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548 [PMID:23721554 DOI: 10.1111/ajt.12212]
141. Castillo-Rama M, Castro MJ, Bernardo I, Meneu-Diaz JC, Elola-Olaso AM, Calleja-Antolin SM, Romo E, Morales P, Moreno E, Paz-Artal E. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562 [PMID: 18383092 DOI: 10.1002/lt.21408]
142. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, Hayashi P, Passannante A, Andreoni K. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368 [PMID: 21445918 DOI: 10.1002/lt.22233]
143. Muro M, Marin L, Miras M, Moya-Quiles R, Minguela A, Sánchez-Bueno F, Bermejo J, Robles R, Ramírez P, García-Alonso A, Parrilla P, Alvarez-López MR. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transpl Immunol 2005; 14: 91-97 [PMID: 15935299]
144. O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, Klintmalm GB, Terasaki PI. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am J Transplant 2011; 11: 1868-1876 [PMID: 21672151 DOI: 10.1111/j.1600-6143.2011.03593.x]
145. Takaya S, Jain A, Yagihashi A, Nakamura K, Kobayashi M, Takeuchi K, Suzuki S, Iwaki Y, Demetris AJ, Todo S, Fung JJ, Starzl TE. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999; 31: 2028-2031 [PMID: 10455963]
146. Opelz G, Döhler B, Süsal C. Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. Hum Immunol 2009; 70: 627-630 [PMID:19375469 DOI: 10.1016/j.humimm.2009.04.009]
147. Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, Heimbach JK. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510 [PMID: 22420671 DOI:10.1111/j.1600-6143.2012.03995.x]
148. Kim YK, Kim SH, Moon IS, Han SS, Cho SY, You T, Park SJ. The effect of a positive T-lymphocytotoxic crossmatch on clinical outcomes in adult-to-adult living donor liver transplantation. J Korean Surg Soc 2013; 84: 245-251 [PMID: 23577320]
149. Shin M, Moon HH, Kim JM, Park JB, Kwon CH, Kim SJ, Lee SK, Joh JW. Significance of true-positive and false-positive pretransplantation lymphocytotoxic crossmatch in primary liver allograft outcomes. Transplantation 2013; 95: 1410-1417 [PMID:23542470 DOI: 10.1097/TP.0b013e31828d155a]
150. Watson R, Kozlowski T, Nickeleit V, Woosley JT, Schmitz JL, Zacks SL, Fair JH, Gerber DA, Andreoni KA. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022-3029 [PMID:17061997]
151. Dar W, Agarwal A, Watkins C, Gebel HM, Bray RA, Kokko KE, Pearson TC, Knechtle SJ. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/ kidney transplants. Am J Transplant 2011; 11: 841-847 [PMID:21446981 DOI: 10.1111/j.1600-6143.2011.03467.x]
152. Aoki T, Sugawara Y, Takahashi M, Kawaguchi Y, Kaneko J, Yamashiki N, Tamura S, Hasegawa K, Takahashi K, Kokudo N. Living donor liver transplantation using sensitized lymphocytotoxic crossmatch positive graft. J Gastroenterol 2012; 47: 486-488 [PMID: 22328021 DOI: 10.1007/s00535-012-0530-2]
153. Koch M, Gräser C, Lehnhardt A, Pollok JM, Kröger N, Verboom M, Thaiss F, Eiermann T, Nashan B. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib. Transpl Int 2013; 26: e64-e68 [PMID: 23672514 DOI: 10.1111/tri.12120]
154. Shindoh J, Sugawara Y, Tamura S, Kaneko J, Yamashiki N, Aoki T, Hasegawa K, Sakamoto Y, Kokudo N. Living donor liver transplantation for patients immunized against human leukocyte antigen. J Hepatobiliary Pancreat Sci 2013; 20: 279-285 [PMID:22407193 DOI: 10.1007/s00534-012-0511-0]
155. Hong G, Yi NJ, Suh SW, Yoo T, Kim H, Park MS, Choi Y, Lee K, Lee KW, Park MH, Suh KS. Preoperative selective desensitization of live donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volume. J Korean Med Sci 2014; 29: 640-647 [PMID: 24851018 DOI: 10.3346/jkms.2014.29.5.640]
156. Lo CM, Shaked A, Busuttil RW. Risk factors for liver transplantation across the ABO barrier. Transplantation 1994; 58:543-547 [PMID: 8091480]
157. Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990; 336:519-523 [PMID: 1975036]
158. Stewart ZA, Locke JE, Montgomery RA, Singer AL, Cameron AM, Segev DL. ABO-incompatible deceased donor liver transplantation in the United States: a national registry analysis. Liver Transpl 2009; 15: 883-893 [PMID: 19642117 DOI: 10.1002/ lt.21723]
159. Kawagishi N, Satomi S. ABO-incompatible living donor liver transplantation: new insights into clinical relevance. Transplantation 2008; 85: 1523-1525 [PMID: 18551048 DOI:10.1097/TP.0b013e318173a70e]
160. Egawa H, Oike F, Buhler L, Shapiro AM, Minamiguchi S, Haga H, Uryuhara K, Kiuchi T, Kaihara S, Tanaka K. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 2004; 77: 403-411 [PMID:14966415]
161. Pratschke J, Tullius SG. Promising recent data on ABO incompatible liver transplantation: restrictions may apply. Transpl Int 2007; 20: 647-648 [PMID: 17610466]
162. Garonzik Wang JM, Montgomery RA, Kucirka LM, Berger JC, Warren DS, Segev DL. Incompatible live-donor kidney transplantation in the United States: results of a national survey. Clin J Am Soc Nephrol 2011; 6: 2041-2046 [PMID: 21784826 DOI: 10.2215/CJN.02940311]
163. Kahwaji J, Vo AA, Jordan SC. ABO blood group incompatibility:a diminishing barrier to successful kidney transplantation? Expert Rev Clin Immunol 2010; 6: 893-900 [PMID: 20979554 DOI:10.1586/eci.10.78]
164. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, Shirey RS, Simpkins CE, Montgomery RA. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-1322 [PMID: 15268734]
165. Tanabe M, Kawachi S, Obara H, Shinoda M, Hibi T, Kitagawa Y, Wakabayashi G, Shimazu M, Kitajima M. Current progress in ABO-incompatible liver transplantation. Eur J Clin Invest 2010; 40: 943-949 [PMID: 20636381 DOI: 10.1111/j.1365-2362.201]
166. Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 2008; 47: 143-152 [PMID:17929298]
167. Morioka D, Sekido H, Kubota K, Sugita M, Tanaka K, Togo S, Yamanaka S, Sasaki T, Inayama Y, Shimada H. Antibody-mediated rejection after adult ABO-incompatible liver transplantation remedied by gamma-globulin bolus infusion combined with plasmapheresis. Transplantation 2004; 78: 1225-1228 [PMID:15502725]
168. Ikegami T, Taketomi A, Soejima Y, Iguchi T, Sanefuji K, Kayashima H, Yoshizumi T, Harada N, Maehara Y. Successful ABO incompatible living donor liver transplantation in a patient with high isoagglutinin titer using high-dose intravenous immunoglobulin. Transplant Proc 2007; 39: 3491-3494 [PMID:18089417]
169. Testa G, Vidanovic V, Chejfec G, Gangemi A, Iqpal R, Porubsky M, Pham T, Benedetti E. Adult living-donor liver transplantation with ABO-incompatible grafts. Transplantation 2008; 85: 681-686 [PMID: 18337660 DOI: 10.1097/TP.0b013e3181665172]
170. Urbani L, Mazzoni A, De Simone P, Catalano G, Coletti L, Montin U, Morelli L, Campani D, Pollina L, Biancofiore G, Bindi L, Scatena F, Filipponi F. Treatment of antibody-mediated rejection with high-dose immunoglobulins in ABO-incompatible liver transplant recipient. Transpl Int 2007; 20: 467-470 [PMID:17263788]
171. Urbani L, Mazzoni A, Bianco I, Grazzini T, De Simone P, Catalano G, Montin U, Petruccelli S, Morelli L, Campani D, Pollina L, Biancofiore G, Bindi L, Tascini C, Menichetti F, Scatena F, Filipponi F. The role of immunomodulation in ABOincompatible adult liver transplant recipients. J Clin Apher 2008; 23: 55-62 [PMID: 18186527 DOI: 10.1002/jca.20156]
172. Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Harada N, Iguchi T, Hashimoto N, Maehara Y. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. Transplantation 2009; 88: 303-307 [PMID: 19667930 DOI:10.1097/TP.0b013e3181adcae6]
173. Takeda K, Tanaka K, Morioka D, Kumamoto T, Endo I, Togo S, Shimada H. Pathogenesis in ABO incompatible liver transplantation: a clinicohistological evaluation of four patients. Clin Transplant 2010; 24: 747-751 [PMID: 19925462 DOI:10.1111/j.1399-0012.2009.01164.x]
174. Mendes M, Ferreira AC, Ferreira A, Remédio F, Aires I, Cordeiro A, Mascarenhas A, Martins A, Pereira P, Gloria H, Perdigoto R, Veloso J, Ferreira P, Oliveira J, Silva M, Barroso E, Nolasco F. ABO-incompatible liver transplantation in acute liver failure:a single Portuguese center study. Transplant Proc 2013; 45:1110-1115 [PMID: 23622639 DOI: 10.1016/j.transproceed.2013.02.012]
175. Kim JD, Choi DL, Han YS. Fourteen successful consecutive cases of ABO-incompatible living donor liver transplantation:new simplified intravenous immunoglobulin protocol without local infusion therapy. Transplant Proc 2014; 46: 754-757 [PMID:24767341 DOI: 10.1016/j.transproceed.2013.11.100]
176. Lee SD, Kim SH, Kong SY, Kim YK, Lee SA, Park SJ. ABOincompatible living donor liver transplantation without graft local infusion and splenectomy. HPB (Oxford) 2014; 16: 807-813 [PMID: 24467804 DOI: 10.1111/hpb.12215]
177. Shen T, Lin BY, Jia JJ, Wang ZY, Wang L, Ling Q, Geng L, Yan S, Zheng SS. A modified protocol with rituximab and intravenous immunoglobulin in emergent ABO-incompatible liver transplantation for acute liver failure. Hepatobiliary Pancreat Dis Int 2014; 13: 395-401 [PMID: 25100124 DOI: 10.1016/j. transproceed]